Physician profile
Andre D Tilton
NPI 1306165097
$8,062.54
in general payments reported to CMS, 2019-2025
39 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $1,340 · 2021: $1,252 · 2022: $1,191 · 2023: $1,484 · 2024: $1,183 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,941.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,847.29 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $1,164.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $728.45 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $688.43 | 2019-2024 | |
| Allergan, INC. | $491.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $386.20 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $371.44 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $286.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $284.98 | 2019-2025 | Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $167.43 | 2022-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $164.46 | 2019-2023 | |
| Orexo US, INC. | $163.33 | 2019-2023 | Zubsolv |
| Ardelyx, INC. | $124.45 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.28 | 2019-2021 | |
| Genentech USA, INC. | $118.42 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Tilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.